Most non-steroidal anti-inflammatory drugs (NSAIDs) used in large animals have significant
potential for adverse effects via inhibition of cyclooxygenase enzymes, such as gastric
ulceration and nephrotoxicity. A new class of anti-inflammatory medications, the priprant
class, act via inhibition of the P4 receptor of prostaglandin E2 and have no effect on
cyclooxygenase enzymes potentially giving them a wider safety margin. Grapiprant is a
medication currently labeled for the treatment of osteoarthritis in dogs and no research is …